durvalumab + anlotinib + carboplatin + nab-paclitaxel

This is an investigational combination therapy consisting of four components: durvalumab (an anti-PD-L1 antibody), anlotinib (a multi-target tyrosine kinase inhibitor), carboplatin (a platinum-based chemotherapy agent), and nab-paclitaxel (an albumin-bound formulation of paclitaxel). Based on the provided search results, this combination appears to be under investigation for the treatment of certain cancers, particularly triple-negative breast cancer and non-small cell lung cancer. The text mentions studies involving subsets of these drugs, such as durvalumab with chemotherapy, anlotinib with taxane and platinum, and durvalumab with carboplatin and nab-paclitaxel in a Phase I trial, suggesting the rationale for exploring this four-drug regimen, although a clinical trial evaluating all four drugs together is not explicitly detailed in the provided text.